Announcements A Joint Statement on Technical, legal, ethical and implementation concerns regarding Aarogya Setu and other apps introduced during COVID-19 in India by Jan Swasthya Abhiyan (JSA), Internet Freedom Foundation (IFF), Forum for Medical Ethics Society (FMES), and All India People’s Science Network (AIPSN)   |   Submission to the National Human Rights Commission (NHRC) on behalf of Hub5 (HEaL Institute, APU, Seher-CHSJ, and IAPH) – COPASAH on human rights issues confronted by ASHAS and ANMs during the Covid-19 pandemic | Aug 7, 2020   |   Letter to MMC by FMES, PUCL-MH, FAOW, and MFC urging to restore its order suspending licenses of two doctors accused of abetting the suicide of Dr Payal Tadvi

Are all new drugs ‘healthy’?

Sujith J Chandy, Atiya R Faruqui

DOI: 10.20529/IJME.2004.006


Abstract

The race for the launch of new drugs, brands and combination drugs has resulted in nearly 50–80 new entries in the market in the year 2002 alone. Is it ‘healthy’ to have such a flooding of the market with new drugs? Do these new drugs really have benefits over their older congeners as most of them claim to have? To answer these questions, we need to look at two important aspects in the field of new drug marketing: safety and claims of superiority.

Full Text

HTML PDF

Keywords

N/A

Refbacks

There are currently no refbacks.

Article Views

PDF Downloads

Click here to support US